Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ENPEP | Q07075 | 7/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 4/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31021037 | 0.88 | OPRM1 (0.41) | OPRM1OPRD1CTSDTERT | |
| SCHEMBL30052307 | 0.88 | ALDH1A1 (0.50) | ALDH1A1ENPEPL3MBTL1TERTCA2 | |
| SCHEMBL29369101 | 0.87 | OPRM1 (0.49) | OPRM1OPRD1TERT | |
| SCHEMBL11061687 | 0.83 | CTSD (0.57) | OPRM1OPRD1CTSD | |
| SCHEMBL11061679 | 0.83 | CTSD (0.57) | OPRM1OPRD1CTSD | |
| SCHEMBL16401109 | 0.82 | ALDH1A1 (0.47) | ALDH1A1ENPEPL3MBTL1CTSDCA2 | |
| SCHEMBL29351781 | 0.82 | MME (0.47) | OPRM1OPRD1TERT | |
| SCHEMBL31257021 | 0.80 | OPRD1 (0.56) | OPRM1OPRD1 | |
| SCHEMBL4088242 | 0.80 | TERT (0.42) | ENPEPOPRM1OPRD1CTSDTERT | |
| SCHEMBL4088244 | 0.80 | TERT (0.42) | ENPEPOPRM1OPRD1CTSDTERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338555-A1 | CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20220243210-A1 | ANGIOTENSIN II TYPE 1 RECEPTOR TARGETED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2022-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338555-A1 | CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | DCLRE1B, RNASE1, LNPEP | ALDH1A1 2512/4885ENPEP 16/4885OPRM1 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.